Infection control wins stimulus funds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

Recipient Colleen Delaney, MD, is an assistant member in the Fred Hutchinson center’s clinical research division. Her goal is to find to ways to reduce the risk of infection, and early death, in patients who receive cord blood transplants.

In her ongoing research, Dr. Delaney developed a novel culture methodology, which demonstrated that neutrophils can be generated from a single unit of cord blood. In addition, these cells are capable of rapid recovery when infused in the clinical setting. These findings could change the way transplant is done.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content